Table 4.
Marine compound
|
Chemical nature
|
Mechanism of action
|
Ref.
|
Elisidepsin | Cyclic peptide | With combination of cisplatin or paclitaxel showed synergistic toxicity on BC cells by reducing the phosphorylation of Akt and inhibiting the MAPK pathway via targeting ErbB expression | Moghtaderi et al[74] |
Sipholenol A | Triterpene | Increased the sensitivity of paclitaxel in BC cells by inhibiting P-gp and MRP1 | Resmi et al[104] and Mohamed et al[105] |
Permethyl ningalin B | Pyrrole-containingcompound | Sensitized BC cells to paclitaxel by inhibiting drug efflux activity of P-gp and increasing drug accumulation | Resmi et al[104] and Mohamed et al[105] |
Trabectedin | Alkaloid | Combination with cisplatin or paclitaxel or doxorubicin showed an additive effect in the preclinical system | Chen et al[75] |
Marine polysaccharide | Polysaccharide | In combination with cisplatin, synergistically inhibited the proliferation and migration by blocking the MMP-2 and MMP-9 expression | Chen et al[75] |
Iturin A | Cyclo-lipopeptide | In combination with docetaxel, substantially sensitized docetaxel-resistant TNBC cells by reducing proliferation via massive arresting at the G1 stage and activating caspase 3 as well as inhibiting Akt and its downstream signaling pathways | Dey et al[119] |
Renieramycin M | Tetrahydro-isoquinoline | Sensitized MCF-7 cells synergistically to doxorubicin by promoting doxorubicin-induced DNA damage, cell cycle arrest, and apoptosis via downregulating ErbB/PI3K-Akt, integrin, and focal adhesion signaling | Tun et al[120] |
Sulfated polysaccharide | - | In combination with pH-sensitive DOX releasing nanosystem inhibited growth and metastasis of BC cells in tumor-bearing mice | Zhang et al[121] |
Papuamine | Pentacyclic alkaloid | Inhibited colony formation of BC cells by targeting activation of JNK | Kanno et al[122] |
BC: Breast cancer; MAPK: Mitogen-activated protein kinase; P-gp: P-glycoprotein; MRP: Multidrug-resistant associated protein; MMP: Matrix metalloproteinase; TNBC: Triple-negative breast cancer; DOX: Doxorubicin; JNK: c-Jun N-terminal kinase.